JP2004533457A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004533457A5 JP2004533457A5 JP2003500062A JP2003500062A JP2004533457A5 JP 2004533457 A5 JP2004533457 A5 JP 2004533457A5 JP 2003500062 A JP2003500062 A JP 2003500062A JP 2003500062 A JP2003500062 A JP 2003500062A JP 2004533457 A5 JP2004533457 A5 JP 2004533457A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- formula
- sulfonamide
- ylmethylphenyl
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 62
- 239000002671 adjuvant Substances 0.000 claims 10
- 239000003085 diluting agent Substances 0.000 claims 10
- 239000008194 pharmaceutical composition Substances 0.000 claims 9
- 150000003839 salts Chemical class 0.000 claims 9
- -1 n- butyl Chemical group 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 208000035475 disorder Diseases 0.000 claims 5
- 238000009472 formulation Methods 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- 201000006549 dyspepsia Diseases 0.000 claims 4
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 4
- 125000001475 halogen functional group Chemical group 0.000 claims 3
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims 3
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 claims 2
- 239000005541 ACE inhibitor Substances 0.000 claims 2
- 101150116411 AGTR2 gene Proteins 0.000 claims 2
- 101710129690 Angiotensin-converting enzyme inhibitor Proteins 0.000 claims 2
- 101710086378 Bradykinin-potentiating and C-type natriuretic peptides Proteins 0.000 claims 2
- IYZVAOAMGHOEHC-UHFFFAOYSA-N C(=O)=NS(=O)(=O)C=1SC(=CC=1C1=CC=C(C=C1)CN1C=NC=C1)CC(C)C Chemical compound C(=O)=NS(=O)(=O)C=1SC(=CC=1C1=CC=C(C=C1)CN1C=NC=C1)CC(C)C IYZVAOAMGHOEHC-UHFFFAOYSA-N 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 2
- 206010020772 Hypertension Diseases 0.000 claims 2
- 208000034486 Multi-organ failure Diseases 0.000 claims 2
- 208000010718 Multiple Organ Failure Diseases 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 239000002333 angiotensin II receptor antagonist Substances 0.000 claims 2
- 239000000400 angiotensin II type 1 receptor blocker Substances 0.000 claims 2
- 229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 claims 2
- 206010012601 diabetes mellitus Diseases 0.000 claims 2
- 206010013781 dry mouth Diseases 0.000 claims 2
- 230000003511 endothelial effect Effects 0.000 claims 2
- 230000001969 hypertrophic effect Effects 0.000 claims 2
- 239000004615 ingredient Substances 0.000 claims 2
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- QMKDXFGVHANNCT-UHFFFAOYSA-N 1-butyl-3-[3-[4-(imidazol-1-ylmethyl)phenyl]-5-(2-methylpropyl)thiophen-2-yl]sulfonylurea Chemical compound S1C(CC(C)C)=CC(C=2C=CC(CN3C=NC=C3)=CC=2)=C1S(=O)(=O)NC(=O)NCCCC QMKDXFGVHANNCT-UHFFFAOYSA-N 0.000 claims 1
- LVOSHIKIHCLWMB-UHFFFAOYSA-N 2-butoxy-n-[3-[4-(imidazol-1-ylmethyl)phenyl]-5-(2-methylpropyl)thiophen-2-yl]sulfonylacetamide Chemical compound S1C(CC(C)C)=CC(C=2C=CC(CN3C=NC=C3)=CC=2)=C1S(=O)(=O)NC(=O)COCCCC LVOSHIKIHCLWMB-UHFFFAOYSA-N 0.000 claims 1
- UZDLZKANCYDPSR-UHFFFAOYSA-N 2-methylpropyl n-[3-[4-(imidazol-1-ylmethyl)phenyl]-5-(2-methylpropyl)thiophen-2-yl]sulfonylcarbamate Chemical compound S1C(CC(C)C)=CC(C=2C=CC(CN3C=NC=C3)=CC=2)=C1S(=O)(=O)NC(=O)OCC(C)C UZDLZKANCYDPSR-UHFFFAOYSA-N 0.000 claims 1
- AWGBKZRMLNVLAF-UHFFFAOYSA-N 3,5-dibromo-n,2-dihydroxybenzamide Chemical compound ONC(=O)C1=CC(Br)=CC(Br)=C1O AWGBKZRMLNVLAF-UHFFFAOYSA-N 0.000 claims 1
- 208000004998 Abdominal Pain Diseases 0.000 claims 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 claims 1
- 206010003178 Arterial thrombosis Diseases 0.000 claims 1
- 201000001320 Atherosclerosis Diseases 0.000 claims 1
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 208000023514 Barrett esophagus Diseases 0.000 claims 1
- 208000023665 Barrett oesophagus Diseases 0.000 claims 1
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 claims 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 claims 1
- 208000006029 Cardiomegaly Diseases 0.000 claims 1
- 206010008088 Cerebral artery embolism Diseases 0.000 claims 1
- 206010008111 Cerebral haemorrhage Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 208000028698 Cognitive impairment Diseases 0.000 claims 1
- 208000002881 Colic Diseases 0.000 claims 1
- 206010009900 Colitis ulcerative Diseases 0.000 claims 1
- 206010010774 Constipation Diseases 0.000 claims 1
- 208000011231 Crohn disease Diseases 0.000 claims 1
- 208000019505 Deglutition disease Diseases 0.000 claims 1
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 1
- 206010012735 Diarrhoea Diseases 0.000 claims 1
- 208000030814 Eating disease Diseases 0.000 claims 1
- 208000010228 Erectile Dysfunction Diseases 0.000 claims 1
- 208000019454 Feeding and Eating disease Diseases 0.000 claims 1
- 208000007882 Gastritis Diseases 0.000 claims 1
- 206010020601 Hyperchlorhydria Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010022562 Intermittent claudication Diseases 0.000 claims 1
- 206010067125 Liver injury Diseases 0.000 claims 1
- 206010028813 Nausea Diseases 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 208000011623 Obstructive Lung disease Diseases 0.000 claims 1
- 206010030216 Oesophagitis Diseases 0.000 claims 1
- 208000011707 Ovulation disease Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- 208000031481 Pathologic Constriction Diseases 0.000 claims 1
- 206010035664 Pneumonia Diseases 0.000 claims 1
- 208000004403 Prostatic Hyperplasia Diseases 0.000 claims 1
- 201000004681 Psoriasis Diseases 0.000 claims 1
- 208000001647 Renal Insufficiency Diseases 0.000 claims 1
- 208000013616 Respiratory Distress Syndrome Diseases 0.000 claims 1
- 206010038933 Retinopathy of prematurity Diseases 0.000 claims 1
- 206010040047 Sepsis Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 208000007107 Stomach Ulcer Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000025865 Ulcer Diseases 0.000 claims 1
- 201000006704 Ulcerative Colitis Diseases 0.000 claims 1
- 206010047249 Venous thrombosis Diseases 0.000 claims 1
- 206010047700 Vomiting Diseases 0.000 claims 1
- 208000005946 Xerostomia Diseases 0.000 claims 1
- 210000000577 adipose tissue Anatomy 0.000 claims 1
- 208000011341 adult acute respiratory distress syndrome Diseases 0.000 claims 1
- 201000000028 adult respiratory distress syndrome Diseases 0.000 claims 1
- 230000008484 agonism Effects 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 claims 1
- IEKPELSFCDOQBA-UHFFFAOYSA-N butyl n-[2-[4-(imidazol-1-ylmethyl)phenyl]-4-(2-methylpropyl)phenyl]sulfonylcarbamate Chemical compound CCCCOC(=O)NS(=O)(=O)C1=CC=C(CC(C)C)C=C1C(C=C1)=CC=C1CN1C=NC=C1 IEKPELSFCDOQBA-UHFFFAOYSA-N 0.000 claims 1
- LBMNAFHGVMWZLF-UHFFFAOYSA-N butyl n-[3-[4-(imidazol-1-ylmethyl)phenyl]-5-(2-methoxyethyl)thiophen-2-yl]sulfonylcarbamate Chemical compound S1C(CCOC)=CC(C=2C=CC(CN3C=NC=C3)=CC=2)=C1S(=O)(=O)NC(=O)OCCCC LBMNAFHGVMWZLF-UHFFFAOYSA-N 0.000 claims 1
- XTEOJPUYZWEXFI-UHFFFAOYSA-N butyl n-[3-[4-(imidazol-1-ylmethyl)phenyl]-5-(2-methylpropyl)thiophen-2-yl]sulfonylcarbamate Chemical compound S1C(CC(C)C)=CC(C=2C=CC(CN3C=NC=C3)=CC=2)=C1S(=O)(=O)NC(=O)OCCCC XTEOJPUYZWEXFI-UHFFFAOYSA-N 0.000 claims 1
- FTQCYFZKKZBBDO-UHFFFAOYSA-N butyl n-[3-[4-[(4-methylimidazol-1-yl)methyl]phenyl]-5-(2-methylpropyl)thiophen-2-yl]sulfonylcarbamate Chemical compound S1C(CC(C)C)=CC(C=2C=CC(CN3C=C(C)N=C3)=CC=2)=C1S(=O)(=O)NC(=O)OCCCC FTQCYFZKKZBBDO-UHFFFAOYSA-N 0.000 claims 1
- CRVUTXCUTSEMJG-UHFFFAOYSA-N butyl n-[5-(2-methylpropyl)-3-[4-(1,2,4-triazol-1-ylmethyl)phenyl]thiophen-2-yl]sulfonylcarbamate Chemical compound S1C(CC(C)C)=CC(C=2C=CC(CN3N=CN=C3)=CC=2)=C1S(=O)(=O)NC(=O)OCCCC CRVUTXCUTSEMJG-UHFFFAOYSA-N 0.000 claims 1
- ALBUOUSMHVDYPH-UHFFFAOYSA-N butyl n-[5-(2-methylpropyl)-3-[4-(pyrazol-1-ylmethyl)phenyl]thiophen-2-yl]sulfonylcarbamate Chemical compound S1C(CC(C)C)=CC(C=2C=CC(CN3N=CC=C3)=CC=2)=C1S(=O)(=O)NC(=O)OCCCC ALBUOUSMHVDYPH-UHFFFAOYSA-N 0.000 claims 1
- YEYBCQMOQPDMCY-UHFFFAOYSA-N butyl n-[5-(2-methylpropyl)-3-[4-(tetrazol-1-ylmethyl)phenyl]thiophen-2-yl]sulfonylcarbamate Chemical compound S1C(CC(C)C)=CC(C=2C=CC(CN3N=NN=C3)=CC=2)=C1S(=O)(=O)NC(=O)OCCCC YEYBCQMOQPDMCY-UHFFFAOYSA-N 0.000 claims 1
- BOAVWPQXLAYBQX-UHFFFAOYSA-N butyl n-[5-(2-methylpropyl)-3-[4-(tetrazol-2-ylmethyl)phenyl]thiophen-2-yl]sulfonylcarbamate Chemical compound S1C(CC(C)C)=CC(C=2C=CC(CN3N=NC=N3)=CC=2)=C1S(=O)(=O)NC(=O)OCCCC BOAVWPQXLAYBQX-UHFFFAOYSA-N 0.000 claims 1
- WIECBDQRUBNGNS-UHFFFAOYSA-N butyl n-[5-(2-methylpropyl)-3-[4-[[3-(trifluoromethyl)pyrazol-1-yl]methyl]phenyl]thiophen-2-yl]sulfonylcarbamate Chemical compound S1C(CC(C)C)=CC(C=2C=CC(CN3N=C(C=C3)C(F)(F)F)=CC=2)=C1S(=O)(=O)NC(=O)OCCCC WIECBDQRUBNGNS-UHFFFAOYSA-N 0.000 claims 1
- LTJMWCDMMKPNCW-UHFFFAOYSA-N butyl n-[5-butyl-3-[4-(imidazol-1-ylmethyl)phenyl]thiophen-2-yl]sulfonylcarbamate Chemical compound S1C(CCCC)=CC(C=2C=CC(CN3C=NC=C3)=CC=2)=C1S(=O)(=O)NC(=O)OCCCC LTJMWCDMMKPNCW-UHFFFAOYSA-N 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 210000000748 cardiovascular system Anatomy 0.000 claims 1
- 230000024245 cell differentiation Effects 0.000 claims 1
- 230000004663 cell proliferation Effects 0.000 claims 1
- 210000003169 central nervous system Anatomy 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 208000026106 cerebrovascular disease Diseases 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 230000006378 damage Effects 0.000 claims 1
- 230000002950 deficient Effects 0.000 claims 1
- 235000014632 disordered eating Nutrition 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 208000000718 duodenal ulcer Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 208000006881 esophagitis Diseases 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- LPYXRTXXLKVWKJ-UHFFFAOYSA-N ethyl n-[3-[4-(imidazol-1-ylmethyl)phenyl]-5-(2-methylpropyl)thiophen-2-yl]sulfonylcarbamate Chemical compound S1C(CC(C)C)=CC(C=2C=CC(CN3C=NC=C3)=CC=2)=C1S(=O)(=O)NC(=O)OCC LPYXRTXXLKVWKJ-UHFFFAOYSA-N 0.000 claims 1
- 210000001508 eye Anatomy 0.000 claims 1
- 208000020694 gallbladder disease Diseases 0.000 claims 1
- 230000002496 gastric effect Effects 0.000 claims 1
- 201000005917 gastric ulcer Diseases 0.000 claims 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims 1
- 210000001035 gastrointestinal tract Anatomy 0.000 claims 1
- 210000004392 genitalia Anatomy 0.000 claims 1
- 231100000234 hepatic damage Toxicity 0.000 claims 1
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 235000003642 hunger Nutrition 0.000 claims 1
- 206010020718 hyperplasia Diseases 0.000 claims 1
- 201000001881 impotence Diseases 0.000 claims 1
- 238000001727 in vivo Methods 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 208000021156 intermittent vascular claudication Diseases 0.000 claims 1
- 208000020658 intracerebral hemorrhage Diseases 0.000 claims 1
- 201000010849 intracranial embolism Diseases 0.000 claims 1
- 230000000302 ischemic effect Effects 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 201000006370 kidney failure Diseases 0.000 claims 1
- 230000008818 liver damage Effects 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- JRELQXXPAXDOSZ-UHFFFAOYSA-N n-butylsulfonyl-3-[4-(imidazol-1-ylmethyl)phenyl]-5-(2-methylpropyl)thiophene-2-carboxamide Chemical compound S1C(CC(C)C)=CC(C=2C=CC(CN3C=NC=C3)=CC=2)=C1C(=O)NS(=O)(=O)CCCC JRELQXXPAXDOSZ-UHFFFAOYSA-N 0.000 claims 1
- NCVDBSQABWZGGA-UHFFFAOYSA-N n-butylsulfonyl-3-[4-(imidazol-1-ylmethyl)phenyl]-5-(2-methylpropyl)thiophene-2-sulfonamide Chemical compound S1C(CC(C)C)=CC(C=2C=CC(CN3C=NC=C3)=CC=2)=C1S(=O)(=O)NS(=O)(=O)CCCC NCVDBSQABWZGGA-UHFFFAOYSA-N 0.000 claims 1
- 230000008693 nausea Effects 0.000 claims 1
- 201000008383 nephritis Diseases 0.000 claims 1
- 230000003961 neuronal insult Effects 0.000 claims 1
- 230000009689 neuronal regeneration Effects 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 230000016087 ovulation Effects 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 201000011461 pre-eclampsia Diseases 0.000 claims 1
- 230000035755 proliferation Effects 0.000 claims 1
- LIBZHQJJLOPSQZ-UHFFFAOYSA-N propan-2-yl n-[3-[4-(imidazol-1-ylmethyl)phenyl]-5-(2-methylpropyl)thiophen-2-yl]sulfonylcarbamate Chemical compound S1C(CC(C)C)=CC(C=2C=CC(CN3C=NC=C3)=CC=2)=C1S(=O)(=O)NC(=O)OC(C)C LIBZHQJJLOPSQZ-UHFFFAOYSA-N 0.000 claims 1
- 201000004240 prostatic hypertrophy Diseases 0.000 claims 1
- 208000002815 pulmonary hypertension Diseases 0.000 claims 1
- 206010038464 renal hypertension Diseases 0.000 claims 1
- 230000000241 respiratory effect Effects 0.000 claims 1
- 230000002207 retinal effect Effects 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 claims 1
- 230000036262 stenosis Effects 0.000 claims 1
- 208000037804 stenosis Diseases 0.000 claims 1
- 230000000638 stimulation Effects 0.000 claims 1
- 206010044008 tonsillitis Diseases 0.000 claims 1
- 231100000397 ulcer Toxicity 0.000 claims 1
- 230000008673 vomiting Effects 0.000 claims 1
Applications Claiming Priority (9)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0113129.1 | 2001-05-31 | ||
| GB0113129A GB0113129D0 (en) | 2001-05-31 | 2001-05-31 | Pharmaceutically-useful compounds |
| GB0121611.8 | 2001-09-07 | ||
| GB0121611A GB0121611D0 (en) | 2001-09-07 | 2001-09-07 | Pharmaceutically-useful-compounds |
| US35095902P | 2002-01-25 | 2002-01-25 | |
| US60/350,959 | 2002-01-25 | ||
| GB0201794A GB0201794D0 (en) | 2002-01-26 | 2002-01-26 | Pharmaceutically-useful compounds |
| GB0201794.5 | 2002-01-26 | ||
| PCT/GB2002/002563 WO2002096883A1 (en) | 2001-05-31 | 2002-05-30 | Tricyclic compounds useful as angiotensin ii agonists |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2004533457A JP2004533457A (ja) | 2004-11-04 |
| JP2004533457A5 true JP2004533457A5 (enrdf_load_stackoverflow) | 2006-01-05 |
| JP4707321B2 JP4707321B2 (ja) | 2011-06-22 |
Family
ID=32872450
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003500062A Expired - Lifetime JP4707321B2 (ja) | 2001-05-31 | 2002-05-30 | アンギオテンシンｉｉアゴニストとして有用な三環式化合物 |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JP4707321B2 (enrdf_load_stackoverflow) |
| KR (1) | KR100938817B1 (enrdf_load_stackoverflow) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2604797C (en) * | 2005-04-12 | 2013-05-28 | Vicore Pharma Ab | New tricyclic angiotensin ii agonists |
| PL2172450T3 (pl) * | 2007-06-20 | 2014-03-31 | Mitsubishi Tanabe Pharma Corp | Nowe pochodne sulfonamidowe kwasu malonowego i ich zastosowanie farmaceutyczne |
| KR102230461B1 (ko) * | 2013-03-15 | 2021-03-22 | 유니버시티 오브 써던 캘리포니아 | 엔지오텐신-관련 질환들의 치료를 위한 방법들, 화합물들 및 조성물들 |
| WO2015152393A1 (ja) * | 2014-04-03 | 2015-10-08 | 国立研究開発法人国立循環器病研究センター | 悪性腫瘍転移抑制用医薬 |
| GB201913603D0 (en) * | 2019-09-20 | 2019-11-06 | Vicore Pharma Ab | New compounds |
| PH12022552413A1 (en) * | 2020-03-19 | 2024-01-08 | Vicore Pharma Ab | Novel compounds useful in the treatment and/or prevention of a disease, disorder or condition associated with angiotensin ii |
| GB202007122D0 (en) * | 2020-05-14 | 2020-07-01 | Vicore Pharma Ab | New process |
| GB202013721D0 (en) * | 2020-09-01 | 2020-10-14 | Vicore Pharma Ab | New compounds |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5198438A (en) * | 1991-05-07 | 1993-03-30 | Merck & Co., Inc. | Angiotensin ii antagonists incorporating a substituted thiophene or furan |
| US5444067A (en) * | 1993-08-30 | 1995-08-22 | Merck & Co., Inc. | Pharmaceutical treatment methods using angiotensin II receptor agonists bearing a thiophene moiety |
| YU78601A (sh) * | 1999-05-05 | 2005-07-19 | Aventis Pharma Deutschland Gmbh. | 1-(p-tienilbenzil)-imidazoli kao agonisti angiotenzin-(1-7)- receptora, postupak za njihovu proizvodnju, njihova primena i farmaceutski preparati koji ih sadrže |
-
2002
- 2002-05-30 KR KR1020037015757A patent/KR100938817B1/ko not_active Expired - Fee Related
- 2002-05-30 JP JP2003500062A patent/JP4707321B2/ja not_active Expired - Lifetime
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008535899A5 (enrdf_load_stackoverflow) | ||
| CN103351389B (zh) | 卤代芳基取代的氨基嘌呤、其组合物，和将其用于治疗的方法 | |
| CN102627609B (zh) | 杂环天冬氨酰蛋白酶抑制剂 | |
| AU2007284562B2 (en) | Using PI3K and MEK modulators in treatments of cancer | |
| JP4598771B2 (ja) | 複素環式化合物 | |
| CN101925572B (zh) | 二氢化茚酰胺化合物制备方法、包含其的药物组合物、及其作为蛋白激酶抑制剂的应用 | |
| US5516775A (en) | Further use of pyrimidine derivatives | |
| CN101622248B (zh) | 用作axl抑制剂的n3-杂芳基取代的三唑和n5-杂芳基取代的三唑 | |
| JP2008535898A5 (enrdf_load_stackoverflow) | ||
| EP1611123B1 (en) | Tie-2 modulators and methods of use | |
| AU2008214372A1 (en) | Therapeutic agents | |
| CA2449150A1 (en) | Tricyclic compounds useful as angiotensin ii agonists | |
| CN104974140B (zh) | 2,3,4,6‑四取代苯‑1,5‑二胺衍生物、其制法与医药上的用途 | |
| TW200412949A (en) | Acylated, heteroaryl-condensed cycloalkenylamines and their use as pharmaceuticals | |
| BRPI0617162B1 (pt) | compostos inibidores de fosfatidilinositol 3-quinase composições farmacêuticas que os contem e métodos de uso dos mesmos | |
| MXPA05002644A (es) | Derivados de pirimidinona como agentes terapeuticos contra procesos de remodelacion, isquemicos e inflamatorios agudos y cronicos. | |
| JP2016519165A (ja) | Ｗｎｔ経路モジュレーターとしてのプリンジオン | |
| JP2004533457A5 (enrdf_load_stackoverflow) | ||
| TWI248934B (en) | Compounds of adenosine A3 receptor ligands and the process for manufacturing the same | |
| WO2001055123A1 (fr) | Composes cycliques a 5 chainons, contenant de l'azote, et medicaments contenant ces composes comme ingredients actifs | |
| TW202110833A (zh) | 新穎環狀緩激肽b2受體拮抗劑 | |
| US5500427A (en) | Cyclic compounds and their use | |
| CN103102352A (zh) | 酪氨酸激酶抑制剂吲哚满酮衍生物 | |
| JP2008535900A5 (enrdf_load_stackoverflow) | ||
| JP4007743B2 (ja) | 血管新生阻害剤 |